Net Income Increases LOVELAND, Colo., Nov. 7 /PRNewswire-FirstCall/
-- Heska Corporation (NASDAQ:HSKA) today reported financial results
for its third quarter ended September 30, 2007. (Logo:
http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO) Heska
Corporation ("Heska" or the "Company") highlights since its third
quarter began in July 2007 were: -- $19.5 million in quarterly
revenue -- the highest third quarter total in company history --
Over $1 million in quarterly net income -- a 17% increase from the
third quarter of 2006 -- The introduction of the HemaTrue(TM)
Veterinary Hematology Analyzer -- The introduction of the
DRI-CHEM(R) 4000 Veterinary Clinical Chemistry Analyzer from Heska
powered by FUJIFILM "In the third quarter of 2007, we launched one
major new diagnostic instrument and paved the way to launch
another," said Robert Grieve, Heska's Chairman and CEO. "We started
2007 with our diagnostic instrumentation efforts strategically
focused on three categories: chemistry, hematology and hand held
instruments. We have now launched new and enhanced products in all
three of these important categories -- and are the only animal
health company to offer a completely reinvented veterinary lab
system in 2007. We are pleased to offer all of these new products
to our customers, who have come to expect the best in advanced
diagnostics from Heska. We are excited by the opportunities our new
product offerings create to build our business." Total Revenue
Total revenue for the third quarter of 2007 was $19.5 million, an
increase of 5% compared to the third quarter of 2006. Total revenue
consists of product revenue, discussed below, and research,
development and other revenue. In the third quarter of 2007,
research, development and other revenue was $491 thousand, up from
$432 thousand in the third quarter of 2006. Segment Product Revenue
Total product revenue for the third quarter of 2007 was $19.0
million, up 5% from $18.2 million in the third quarter of 2006.
Heska Corporation's business is comprised of two reportable
segments -- Core Companion Animal Health and Other Vaccines,
Pharmaceuticals and Products. Product revenue from these segments
is as follows: Core Companion Animal Health This segment includes
revenue from the company's diagnostic and monitoring instruments
and supplies as well as single use, point-of-care tests, vaccines
and pharmaceuticals, primarily for canine and feline use. In the
third quarter of 2007, this segment generated product revenue of
$15.6 million, down slightly when compared to the third quarter of
2006. At September 30, 2007, the Company had approximately $756
thousand in customer orders for its new HemaTrue(TM) Hematology
Analyzer which the Company did not have inventory to fulfill. The
Company shipped analyzers under these customer orders in the fourth
quarter of 2007. Other Vaccines, Pharmaceuticals and Products This
segment includes revenue from private label vaccine and
pharmaceutical production, primarily for cattle but also for other
animals including small mammals and fish. In the third quarter of
2007, this segment generated product revenue of $3.4 million, up
33% compared to $2.6 million in the third quarter of 2006. The
results for the nine months ended September 30, 2007 include
approximately $1.6 million in revenue recognized in the first
quarter upon receipt of a payment for product previously shipped
and "take-or-pay" minimums for 2005 and 2006 which previously had
not been paid as part of a now settled dispute with United
Vaccines, Inc. ("United"), a former customer. Investor Conference
Call Management will conduct a conference call on Wednesday,
November 7, 2007 at 9:00 a.m. MST (11:00 a.m. EST) to discuss the
third quarter 2007 financial results. To participate, dial (800)
218-8862 (domestic) or (303) 262-2140 (international); the
conference call access number is 11097390. The conference call will
also be broadcast live over the Internet at http://www.heska.com/.
To listen, simply log on to the web at this address at least ten
minutes prior to the start of the call to register, download and
install any necessary audio software. Telephone replays of the
conference call will be available for playback until November 21,
2007. The telephone replay may be accessed by dialing (800)
405-2236 (domestic) or (303) 590-3000 (international). The webcast
replay may be accessed from Heska's home page at
http://www.heska.com/ until November 21, 2007. About Heska Heska
Corporation (NASDAQ:HSKA) sells advanced veterinary diagnostic and
other specialty veterinary products. Heska's state-of-the-art
offerings to its customers include diagnostic and monitoring
instruments and supplies as well as single use, point-of-care
tests, vaccines and pharmaceuticals. The company's core focus is on
the canine and feline markets where it strives to provide high
value products and unparalleled customer support to veterinarians.
For further information on Heska and its products, visit the
company's website at http://www.heska.com/. Forward-Looking
Statements This announcement contains forward-looking statements
regarding Heska's future financial and operating results. These
statements are based on current expectations and are subject to a
number of risks and uncertainties. Investors should note that there
is an inherent risk in using past results to predict future
outcomes. Revenue recognized in the nine months ended September 30,
2007 may not recur in future periods. For example, in the nine
months ended September 30, 2007, Heska recognized approximately
$1.6 million in revenue upon receipt of a payment from United for
product previously shipped and "take or pay" minimums for 2005 and
2006. As United has ceased operations, Heska does not expect to
generate any future revenue from United. In addition, factors that
could affect the business and financial results of Heska generally
include the following: risks regarding the commercialization and
market acceptance of products Heska has introduced recently or may
introduce in the future; risks regarding Heska's reliance on
third-party suppliers, which is substantial and could have
significant negative consequences if such a supplier were unable to
provide appropriate quantity and quality of products or if Heska
were to lose exclusive rights or access to a product; risks related
to relying on the reputation of Heska, FUJIFILM Corporation or any
other entity, which is subject to interpretation and may change
over time; risks regarding Heska's ability to successfully market,
sell and distribute its products; competition; uncertainties
regarding Heska's reliance on third parties to whom Heska has
granted substantial marketing rights to certain of Heska's existing
products; uncertainties regarding the outcome of relationships and
collaborations with third parties from which Heska is hoping to
generate new products; risks related to unanticipated revenue
fluctuations and the corresponding impact on Heska's liquidity and
cash flow as many of Heska's expenses are fixed; and the risks set
forth in Heska's filings and future filings with the Securities and
Exchange Commission, including those set forth in Heska's Annual
Report on Form 10-K for the year ended December 31, 2006 and
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.
Consolidated Statements of Operations In Thousands, Except per
Share Amounts (unaudited) Three Months Ended Nine Months Ended
September 30, September 30, 2006 2007 2006 2007 Revenue, net:
Product revenue, net: Core companion animal health $15,612 $15,601
$44,523 $48,828 Other vaccines, pharmaceuticals and products 2,561
3,399 8,790 12,262 Total product revenue, net 18,173 19,000 53,313
61,090 Research, development and other 432 491 1,329 1,203 Total
revenue 18,605 19,491 54,642 62,293 Cost of revenue: Cost of
products sold 10,348 11,825 31,355 35,790 Cost of research,
development and other 321 58 869 234 Total cost of revenue 10,669
11,883 32,224 36,024 Gross profit 7,936 7,608 22,418 26,269
Operating expenses: Selling and marketing 3,490 3,795 10,771 12,172
Research and development 814 663 2,663 2,109 General and
administrative 2,482 2,017 7,170 7,042 (Gain) on sale of assets - -
- (47) Total operating expenses 6,786 6,475 20,604 21,276 Income
from operations 1,150 1,133 1,814 4,993 Interest and other expense,
net 263 94 809 433 Income before income taxes 887 1,039 1,005 4,560
Income tax expense 23 27 78 121 Net income $864 $1,012 $927 $4,439
Basic net income per share $0.02 $0.02 $0.02 $0.09 Diluted net
income per share $0.02 $0.02 $0.02 $0.08 Shares used for basic net
income per share 50,411 51,269 50,264 51,008 Shares used for
diluted net income per share 52,940 56,173 52,442 55,458 Balance
Sheet Data In Thousands (unaudited) December 31, September 30, 2006
2007 Cash and cash equivalents $5,275 $5,308 Total current assets
30,652 30,059 Total assets 38,495 40,454 Line of credit 8,022 7,926
Current portion of long-term debt and capital leases 1,275 776
Total current liabilities 21,980 20,264 Long-term debt and capital
leases 1,927 1,345 Stockholders' equity 6,748 12,169
http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO
http://photoarchive.ap.org/ DATASOURCE: Heska Corporation CONTACT:
Jason Napolitano, Executive Vice President & CFO of Heska
Corporation, +1-970-493-7272, ext. 4105 Web site:
http://www.heska.com/
Copyright
Heska (NASDAQ:HSKA)
Historical Stock Chart
From May 2024 to Jun 2024
Heska (NASDAQ:HSKA)
Historical Stock Chart
From Jun 2023 to Jun 2024